KUN

[WallStreetnBio]

KUN is a new IPO that touched $8 before settling at $6. The float is only 3.91 Million shares! The CEO said they now have plenty of cash to grow the business now that they are listed on the AMEX so I doubt they will issue more shares and dilute share holder value anytime soon. KUN is a small pharmacutical company that reminds me of AOB when they IPO'ed. The bottom line is with a float this small get in while you can! Its going to pop like SILC did and they had, if I remember right, a 16 million share float.

[setravis]

Press Release Source: China Shenghuo Pharmaceutical Holdings, Inc.


China Shenghuo Pharmaceutical Holdings, Inc. Retains CCG Elite
Thursday June 21, 9:00 am ET


LOS ANGELES, Calif. and KUNMING, China, June 21 /Xinhua-PRNewswire- FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (Amex: KUN - News), a leading specialty pharmaceutical company engaged in researching, developing, manufacturing and marketing Sanchi-based medicinal products in the People's Republic of China ("PRC"), today announced it has retained CCG Elite to design and execute its investor relations campaign.


"China Shenghuo is one of the promising high-growth companies in China's emerging pharmaceutical market," said Crocker Coulson, President of CCG Elite. "The Company's historical revenue growth and capacity to develop and manufacture Sanchi for a variety of uses positions China Shenghuo as a very attractive investment vehicle that leverages the high growth rate of the traditional Chinese medicine industry in China."

In the first quarter of 2007, revenues were $4.3 million, while the Company's gross profit increased 11.4% year-over-year to $3.2 million. Gross margin was 73.6%, up from 63.9% in the first quarter of 2006. The Company expects gross margin to be approximately 60% for the full year 2007. Net income was $1.5 million, or $0.08 per diluted share, a 77.3% increase from $0.8 million, or $0.05 per diluted share, in the same quarter of 2006. The Company's stock began trading on the American Stock Exchange June 14, 2007, under the ticker symbol "KUN".

"China Shenghuo has strong brand recognition as we market our major Sanchi-based pharmaceutical products under the popular Lixuwang brand," said Mr. Lan Guihua, Chief Executive Officer and Chairman of China Shenghuo. "By emphasizing investment in scientific research and quality control, we have elevated the development of prescription and over-the-counter products based on traditional Chinese medicine practices."

Through its four subsidiaries, the Company has a diverse product portfolio, including pharmaceuticals, nutritional supplements and cosmetic products. The flagship product, Xuesaitong Soft Capsules, has been listed in the National Insurance Catalogue since 2005. China Shenghuo's integrated sales network spans more than 20 provinces in China.

The Company's state-of-the-art factories in the Kunming National Economy & Technology Developing District in mainland China have a combined production capacity of 1.5 billion soft capsules per year. China Shenghuo's advanced manufacturing procedures and effective quality control enable it to provide pharmaceutical products according to more stringent Western standards.

About CCG Elite

CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene and a direct pipeline into the leading funds and broker-dealers in the U.S. CCG Elite is a global, full-service investor relations agency with corporate headquarters in Los Angeles and offices in New York City, Newport Beach, Calif., Dallas, Texas, Hong Kong and Beijing. For further information, contact CCG Elite directly, or visit the Company's Web site at http://www.ccgelite.com .

About China Shenghuo Pharmaceutical Holdings, Inc.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the Company") is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500 drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Thailand and Kyrgyzstan.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth herein that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to conduct the company's business and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    China Shenghuo Pharmaceutical Holdings, Inc.
     Ms. Gao Qionghua, CFO
     Tel:   +86-871-728-2608
     Email: [email protected]

    CCG Elite Investor Relations
     Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)
     Email: [email protected]
--------------------------------------------------------------------------------
Source: China Shenghuo Pharmaceutical Holdings, Inc.

[WallStreetnBio]

It doesn't take much money to swing KUN either way. $5 is acting as a bottom for KUN. I think the reason $5 is a bottom is because shorts cant short below $5 and push it lower.  With the float so small this stock will take off. Get in while you can!

[WallStreetnBio]

I would like to hear other peoples comments on KUN.  Has anybody even looked at this stock?

[WallStreetnBio]

There are no shares available for shorting. These shorts will begin to cover when they realize its not going below $5. I expect $8 in two weeks. When it starts to move up a bit it will jump fast.

[kslifka]

Bought this on fire China drug stock this morning.  Then bought more when it flat-lined around $12.  Sold the second half at close.  Looks good here to more higher

[BigSully1]

Fantastic move off the bottom .

[BigSully1]

update